Company news
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) news
Crinetics Pharmaceuticals, Inc. news releases on 6ix. Latest, Aug 3, 2026: Crinetics Pharmaceuticals Reports Second Quarter 2026 Financial Results…
Press releases & updates
Crinetics Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
August 3, 2026
Crinetics Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Crinetics Pharmaceuticals, Inc. - CRNX
July 8, 2026
Vertex to Acquire Crinetics Pharmaceuticals
July 5, 2026
Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control
June 14, 2026
Crinetics and Leading Patient Groups Launch ‘Everyday Advocacy’ Initiative to Empower People Across Endocrine Disease Communities
June 2, 2026
Crinetics’ Paradigm-Shifting Portfolio and Pipeline on Display at ENDO 2026 with Six Presentations
June 2, 2026
Crinetics Pharmaceuticals to Participate in Jefferies Global Healthcare Conference 2026
May 22, 2026
Crinetics Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
May 7, 2026
Crinetics Pharmaceuticals Announces the European Commission Approval of PALSONIFY® (Paltusotine) for the Treatment of Acromegaly in Adults
April 27, 2026
Neutrolis Appoints Caren Deardorf as Chief Business & Strategy Officer
April 15, 2026
Crinetics Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026
April 7, 2026
Crinetics Pharmaceuticals : Announces Submission of Marketing Authorization Application in Brazil for Palsonify™ (Paltusotine) in Acromegaly
March 25, 2026
Crinetics Pharmaceuticals Announces Submission of Marketing Authorization Application in Brazil for Palsonify™ (Paltusotine) in Acromegaly
March 25, 2026
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
February 26, 2026
Crinetics Pharmaceuticals : Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
February 25, 2026
Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences in March
February 5, 2026
Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
January 25, 2026
Crinetics Initiates Phase 2/3 Pediatric Trial Evaluating Atumelnant in Congenital Adrenal Hyperplasia (CAH)
January 22, 2026
Crinetics Pharmaceuticals Announces January 2026 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 12, 2026
Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock
January 5, 2026
Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
January 4, 2026
Crinetics Announces Strong PALSONIFY Launch Execution and Positive Results for Concurrent Androstenedione Lowering and Glucocorticoid Dose Reduction in Phase 2 Trial of Atumelnant for Congenital Adrenal Hyperplasia
January 4, 2026
Crinetics Pharmaceuticals to Provide PALSONIFY Business Update and Announce Topline Results from Fourth Cohort of Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia
January 3, 2026
Crinetics Pharmaceuticals to Participate in The 44th Annual J.P. Morgan Healthcare Conference
December 17, 2025
Crinetics Announces First Patient Dosed in Pivotal Adult Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH)
December 10, 2025
Crinetics Pharmaceuticals Announces December 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 9, 2025
Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and Other Somatostatin Receptor 2-Expressing Tumors
December 2, 2025
Crinetics Announces First Patient Randomized in Pivotal Phase 3 CAREFNDR Trial Evaluating Paltusotine in Carcinoid Syndrome
November 19, 2025
Crinetics Pharmaceuticals Announces November 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 9, 2025
Crinetics Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
November 5, 2025
Crinetics to Highlight Neuroendocrine Tumor Research Progress at the 2025 North American Neuroendocrine Tumor Society Annual Meeting
October 22, 2025
Crinetics Pharmaceuticals Announces October 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 9, 2025
Crinetics Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025
October 5, 2025
Crinetics Announces FDA Approval of PALSONIFY™ (paltusotine) for the Treatment of Adults with Acromegaly
September 24, 2025
Crinetics Pharmaceuticals Announces September 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 9, 2025
Crinetics Receives FDA Orphan Drug Designation for Atumelnant in the Treatment of Congenital Adrenal Hyperplasia (CAH)
August 20, 2025
Crinetics Pharmaceuticals Announces August 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 10, 2025
Crinetics Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
August 6, 2025
Crinetics to Present New Long-Term Data Demonstrating Durable Control of Once-Daily, Oral PALSONIFY™ (Paltusotine) in Acromegaly at ENDO 2025
July 12, 2025
Crinetics Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025
July 10, 2025
Crinetics Pharmaceuticals Announces July 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 9, 2025
Crinetics to Showcase the Next Generation of Endocrinology Innovation at ENDO 2025 with Eight Presentations From its Deep Pipeline
June 29, 2025
Crinetics Pharmaceuticals to Host R&D Day on June 26, 2025
June 15, 2025
Crinetics Pharmaceuticals Announces June 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 9, 2025
Crinetics Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2025
May 22, 2025
Crinetics to Present New Research on Paltusotine, Atumelnant and Unmet Needs in Acromegaly Treatment at the American Association of Clinical Endocrinology Annual Meeting 2025
May 14, 2025
Crinetics Pharmaceuticals Announces May 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 11, 2025
Crinetics Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
May 7, 2025
Crinetics Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025
April 10, 2025
Crinetics Pharmaceuticals Announces April 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 9, 2025